Closed-Loop Insulin Delivery System Using a Continuous Glucose Monitor: Performance in a Simulated Environment

Authors

DOI:

https://doi.org/10.5281/zenodo.22485966

Keywords:

closed-loop insulin delivery, continuous glucose monitoring, artificial pancreas, type 1 diabetes, in silico simulation

Abstract

Background: Closed-loop insulin delivery systems combining continuous glucose monitors (CGMs), insulin pumps, and dosing algorithms are increasingly used to manage type 1 diabetes, and their algorithms are developed and pre-validated using computer simulation before human testing. Objective: This narrative review synthesizes published evidence on CGM-driven closed-loop systems, from in silico development through clinical and real-world outcomes. Methods: We reviewed randomized controlled trials, meta-analyses, real-world registries, and simulation-methodology literature on hybrid closed-loop, bihormonal, and open-source automated insulin delivery systems, including the UVA/Padova Type 1 Diabetes Simulator. Findings: Simulation platforms accepted by regulators as substitutes for early animal testing have supported the development of systems such as Control-IQ, MiniMed 780G, and CamAPS FX; subsequent randomized trials and real-world registries consistently show increased time-in-range and reduced hypoglycemia versus sensor-augmented pump therapy across pediatric, adult, and pregnant populations, alongside favorable cost-effectiveness modeling. Conclusions: Simulation-guided algorithm development, followed by clinical and real-world validation, has produced consistent glycemic benefits, though exercise-related excursions and access barriers remain unresolved challenges.

References

The Diabetes Control and Complications Trial Research Group (1993). The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 329(14), 977-986. https://doi.org/10.1056/NEJM199309303291401

Nathan DM, Cleary PA, Backlund JC, Genuth SM, Lachin JM, Orchard TJ, et al. (2005). Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine, 353(25), 2643-2653. https://doi.org/10.1056/NEJMoa052187

Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. (2013). Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia. New England Journal of Medicine, 369(3), 224-232. https://doi.org/10.1056/NEJMoa1303576

Bequette BW (2013). Algorithms for a Closed-Loop Artificial Pancreas: The Case for Model Predictive Control. Journal of Diabetes Science and Technology, 7(6), 1632-1643. https://doi.org/10.1177/193229681300700624

Kovatchev BP, Breton M, Man CD, Cobelli C (2009). In Silico Preclinical Trials: Methodology and Engineering Guide to Closed-Loop Control in Type 1 Diabetes Mellitus. Journal of Diabetes Science and Technology, 3(1), 44-55. https://doi.org/10.1177/193229680900300106

Dalla Man C, Micheletto F, Lv D, Breton M, Kovatchev B, Cobelli C (2014). The UVA/PADOVA Type 1 Diabetes Simulator: New Features. Journal of Diabetes Science and Technology, 8(1), 26-34. https://doi.org/10.1177/1932296813514502

Cobelli C, Kovatchev B (2023). Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. Journal of Diabetes Science and Technology, 17(6), 1493-1505. https://doi.org/10.1177/19322968231195081

Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): systematic review and meta-analysis (2022). Diabetology & Metabolic Syndrome, 14, 180. https://doi.org/10.1186/s13098-022-00962-2

Asarani NAM, Reynolds AN, Elbalshy M, Burnside M, de Bock M, Lewis DM, Wheeler BJ (2021). Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic review. Acta Diabetologica, 58(5), 539-547. https://doi.org/10.1007/s00592-020-01623-4

Lewis D, Leibrand S, #OpenAPS Community (2016). Real-World Use of Open Source Artificial Pancreas Systems. Journal of Diabetes Science and Technology, 10(6), 1411. https://doi.org/10.1177/1932296816665635

Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, Laffel LM, et al. (2019). Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New England Journal of Medicine, 381(18), 1707-1717. https://doi.org/10.1056/NEJMoa1907863

Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, Thankamony A, et al. (2022). Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. New England Journal of Medicine, 386(3), 209-219. https://doi.org/10.1056/NEJMoa2111673

Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, et al. (2022). Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health, 4(4), e245-e255. https://doi.org/10.1016/S2589-7500(22)00020-6

Hood KK, et al. (2022). Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes, Obesity and Metabolism, 24(10), 2113-2119. https://doi.org/10.1111/dom.14815

Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, et al. (2014). Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes. New England Journal of Medicine, 371(4), 313-325. https://doi.org/10.1056/NEJMoa1314474

Bionic Pancreas Research Group (2022). Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. New England Journal of Medicine, 387(13), 1161-1172. https://doi.org/10.1056/NEJMoa2205225

Lee TTM, Collett C, Bergford S, Hartnell S, Scott EM, Lindsay RS, et al. (2023). Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. New England Journal of Medicine, 389(17), 1566-1578. https://doi.org/10.1056/NEJMoa2303911

Burnside MJ, Lewis DM, Crocket HR, Meier RA, Williman JA, Sanders OJ, et al. (2022). Open-Source Automated Insulin Delivery in Type 1 Diabetes. New England Journal of Medicine, 387(10), 869-881. https://doi.org/10.1056/NEJMoa2203913

Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, et al. (2015). Home Use of an Artificial Beta Cell in Type 1 Diabetes. New England Journal of Medicine, 373(22), 2129-2140. https://doi.org/10.1056/NEJMoa1509351

Arrieta A, Battelino T, Scaramuzza AE, Da Silva J, Castañeda J, Cordero TL, et al. (2022). Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12,870 real-world users. Diabetes, Obesity and Metabolism, 24(7), 1370-1379. https://doi.org/10.1111/dom.14714

Nanayakkara N, Sharifi A, Burren D, Elghattis Y, Jayarathna DK, Cohen N (2024). Hybrid Closed Loop Using a Do-It-Yourself Artificial Pancreas System in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 18(3), 610-618. https://doi.org/10.1177/19322968231153882

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. (2019). Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 42(8), 1593-1603. https://doi.org/10.2337/dci19-0028

Breton MD, Cherñavvsky DR, Forlenza GP, DeBoer MD, Robic J, Wadwa RP, et al. (2017). Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. Diabetologia, 60(9), 1841-1844. https://doi.org/10.1007/s00125-017-4395-z

Paldus B, Morrison D, Lee M, Zaharieva DP, Riddell MC, O'Neal DN (2023). Strengths and Challenges of Closed-Loop Insulin Delivery During Exercise in People With Type 1 Diabetes: Potential Future Directions. Journal of Diabetes Science and Technology, 17(4), 1077-1087. https://doi.org/10.1177/19322968221088327

Jendle J, Buompensiere MI, Holm AL, Malkin SJP, Cellek S, Fernando J, et al. (2021). The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. Diabetes Therapy, 12(11), 2977-2991. https://doi.org/10.1007/s13300-021-01157-0

Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling (2023). NIHR Health Technology Assessment. https://doi.org/10.3310/jypl3536

Downloads

Published

2024-07-16